Is Krystal Biotech, Inc. overvalued or undervalued?

As of 7 November 2025, Krystal Biotech, Inc. has moved from an expensive to a fair valuation grade. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 27, a Price to Book Value of 4.02, and an EV to EBITDA ratio of 23.83. In comparison to its peers, Krystal's P/E ratio is higher than Halozyme Therapeutics, Inc. at 15.92 and Elanco Animal Health, Inc. at 19.25, indicating a premium valuation relative to these companies.
The PEG ratio of 0.25 suggests that the stock may be undervalued in terms of its growth prospects, especially when compared to the industry average. Additionally, Krystal Biotech has delivered strong returns, outperforming the S&P 500 with a year-to-date return of 26.34% compared to the index's 14.40%. Overall, the valuation metrics and strong performance suggest that Krystal Biotech is fairly valued at this time.